$BBIO Cashflow Statement | Understand Stock

$BBIO

$69.37 +$1.22 (1.79%) Close

$BBIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Loss on extinguishments of debt
Acquired in-process research and development assets
Accretion of debt
Fair value adjustment of warrants
Noncash interest expense on deferred royalty obligations
Amortization of debt discount and issuance costs
Financing Agreement
Funding Agreement
Total financing Agreement
Total amortization of debt discount and issuance costs
Depreciation and amortization
Noncash lease expense
Net loss from equity method investments
Change in fair value of the embedded derivative associated with the deferred royalty obligation
Noncash income from equity method investments
(Gain) loss on deconsolidation of subsidiaries
Gain from investment in equity securities, net
Fair value of shares issued under a license agreement
Loss on sale of certain assets
Impairment of long-lived assets
Gain from sale of priority review voucher, excluding transaction costs
Gain from recognition of receivable from licensing and collaboration agreement
LEO call option income
Accrual of payment-in-kind interest on term loan
Other noncash adjustments, net

Changes in operating assets and liabilities:
Accounts receivable, net
Receivable from a related party
Inventories
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued compensation and benefits
Accrued research and development liabilities
Accrued professional services
Operating lease liabilities
Deferred revenue
Other liabilities

Net cash used in operating activities
Investing activities:
Sales of marketable securities
Purchases of investment in equity securities
Sales of investment in equity securities
Purchases of marketable securities
Maturities of marketable securities
Purchases of investments in equity securities
Proceeds from sales of investments in equity securities
Proceeds from special cash dividends received from an investment in equity securities
Payment for intangible assets
Proceeds from sale of priority review voucher
Proceeds from sale of certain assets
Purchases of property and equipment
Other investing activities
Increase in cash and cash equivalents from consolidation of PellePharm
Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries
Net cash provided by (used in) investing activities

Financing activities:
Proceeds from issuance of common stock through Private Placement offering, net
Proceeds from royalty obligation under Funding Agreement
Issuance costs and discounts associated with royalty obligation under Funding Agreement
Proceeds from issuance of 2031 Notes
2031 Notes, net
Total proceeds from issuance of 2031 Notes
Issuance costs and discounts associated with 2031 Notes/ Issuance costs and discounts associated with term loan under Amended Financing Agreement
2031 Notes, net
Financing Agreement
Total issuance costs and discounts associated with 2031 Notes/ Issuance costs and discounts associated with term loan under Amended Financing Agreement
Purchase of capped calls
Repurchase of common stock
Proceeds from royalty obligation
Royalty Interest Purchase and Sale Agreement
Funding Agreement
Issuance costs and discounts associated with a royalty obligation
Royalty Interest Purchase and Sale Agreement
Funding Agreement
Proceeds from term loan under the Amended Financing Agreement
Repayment of term loans
Funding Agreement
Total repayment of term loans
Repayments of deferred royalty obligations
Proceeds from issuance of common stock through public offerings, net
Repurchase of noncontrolling interest
Proceeds from issuance of common stock through ATM offering, net
Proceeds from common stock issuances under ESPP
Proceeds from stock option exercises, net of repurchases
Proceeds from at-the-market issuance of noncontrolling interest by Eidos, net
Repurchase of Eidos noncontrolling interest, including direct transaction costs
Transactions with noncontrolling interests
Repurchase of RSU shares to satisfy tax withholding
Other financing activities
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of year
Cash, cash equivalents, and restricted cash at end of year
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest
Cash paid for income taxes
Supplemental Disclosures of Noncash Investing and Financing Information:
Unpaid property and equipment
Intangible assets recorded in other accrued and other long-term liabilities
Leasehold improvements paid by landlord
Transfers to noncontrolling interests
Recognition of property and equipment previously classified in other assets
Noncash contribution by a noncontrolling interest
Recognized intangible asset recorded in "Accrued research and development liabilities"
Payment-in-kind interest added to principal of term loan
Deferred merger transaction costs included in accounts payable and accrued professional services
Unpaid debt issuance costs
Net noncash portion of repurchase of Eidos noncontrolling interests
Direct transaction costs in the repurchase of Eidos recorded in additional paid-in capital previously classified in prepaid expenses and other current assets

Reconciliation of Cash, Cash Equivalents and Restricted Cash:
Cash and cash equivalents
Restricted cash — Included in “Prepaid expenses and other current assets”
Restricted cash — Included in “Other assets”
Total cash, cash equivalents and restricted cash at end of years shown on the consolidated statements of cash flows

Comments